Literature DB >> 11241233

Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma.

S Mestiri1, N Bouaouina, S B Ahmed, A Khedhaier, B B Jrad, S Remadi, L Chouchane.   

Abstract

BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) and stress proteins (heat shock proteins) are determining factors in the immune response to tumor cells. The authors designated a large study to investigate the susceptibility and prognostic implications of the genetic variation in TNF-alpha and hsp70-2 in breast carcinoma.
METHODS: The authors used the polymerase chain reaction and restriction enzyme digestion to characterize the variation of the TNF-alpha promoter region and that of the hsp70-2 gene in 243 unrelated Tunisian patients with breast carcinoma and 174 healthy control subjects. Associations of the clinicopathologic parameters and the genetic markers with the rates of the breast carcinoma specific overall survival and the disease free survival (DFS) were assessed using univariate and multivariate analyses.
RESULTS: A highly significant association was found between TNF2 homozygous genotype and breast carcinoma (relative risk [RR], 4.44; P = 0.006). A high relative risk of breast carcinoma was found to be associated with one hsp70-2 homozygous genotype (P2/P2; RR, 7.12; P = 0.0001). The TNF2 homozygous genotype showed a significant association with reduced DFS and/or overall survival by univariate test. Conversely, P2-hsp70-2 homozygous genotype associated with increased overall survival but not with DFS. Multivariate analysis retained significance for TNF2 homozygous genotype as an independent prognostic indicator for both DFS (RR, 2.75; P = 0.01) and overall survival (RR, 4.08; P = 0.01).
CONCLUSIONS: Genetic variation in TNF-alpha and hsp70-2 may represent not only markers for the increased risk of breast carcinoma but also may predict the clinical outcome. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241233     DOI: 10.1002/1097-0142(20010215)91:4<672::aid-cncr1050>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  40 in total

1.  HLA class II polymorphism: protective or risk factors to breast cancer in Tunisia?

Authors:  Amal Baccar Harrath; Besma Yacoubi Loueslati; Wafa Troudi; Slama Hmida; Syrine Sedkaoui; Amel Dridi; Afef Jridi; Farhat Ben Ayed; Khaled Ben Rhomdhane; Amel Ben Ammar Elgaaied
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

2.  Genetic variants in TNF-α promoter are predictors of recurrence in patients with squamous cell carcinoma of oropharynx after definitive radiotherapy.

Authors:  Caiyun Zhang; Erich M Sturgis; Hongliang Zheng; Xicheng Song; Peng Wei; Lei Jin; Li Chao; Qingyi Wei; Guojun Li
Journal:  Int J Cancer       Date:  2013-10-24       Impact factor: 7.396

3.  The tumor necrosis factor-α-238 polymorphism and digestive system cancer risk: a meta-analysis.

Authors:  Ming Hui; Xiaojuan Yan; Ying Jiang
Journal:  Clin Exp Med       Date:  2015-06-06       Impact factor: 3.984

Review 4.  Interleukin-10 polymorphisms, cancer susceptibility and prognosis.

Authors:  W Martin Howell; Matthew J Rose-Zerilli
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

5.  Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk.

Authors:  Mia M Gaudet; Kathleen M Egan; Jolanta Lissowska; Polly A Newcomb; Louise A Brinton; Linda Titus-Ernstoff; Meredith Yeager; Stephen Chanock; Robert Welch; Beata Peplonska; Amy Trentham-Dietz; Montserrat Garcia-Closas
Journal:  Hum Genet       Date:  2007-01-11       Impact factor: 4.132

6.  Genetic variation in TNFα, PPARγ, and IRS-1 genes, and their association with breast-cancer survival in the HEAL cohort.

Authors:  Catherine Duggan; Richard N Baumgartner; Kathy B Baumgartner; Leslie Bernstein; Stephanie George; Rachel Ballard; Marian L Neuhouser; Anne McTiernan
Journal:  Breast Cancer Res Treat       Date:  2017-12-18       Impact factor: 4.872

7.  TNF-α promoter polymorphisms and risk of recurrence in patients with squamous cell carcinomas of the nonoropharynx.

Authors:  Caiyun Zhang; Erich M Sturgis; Hongliang Zheng; Mark E Zafereo; Qingyi Wei; Guojun Li
Journal:  Int J Cancer       Date:  2014-02-27       Impact factor: 7.396

8.  HLA complex-linked heat shock protein genes and childhood acute lymphoblastic leukemia susceptibility.

Authors:  Esma Ucisik-Akkaya; Charronne F Davis; Clara Gorodezky; Carmen Alaez; M Tevfik Dorak
Journal:  Cell Stress Chaperones       Date:  2009-12-09       Impact factor: 3.667

9.  HSP90, HSPA8, HIF-1 alpha and HSP70-2 polymorphisms in breast cancer: a case-control study.

Authors:  Flora Zagouri; Theodoros N Sergentanis; Maria Gazouli; Alexandra Tsigginou; Constantine Dimitrakakis; Irene Papaspyrou; Evaggelos Eleutherakis-Papaiakovou; Dimosthenis Chrysikos; George Theodoropoulos; George C Zografos; Aris Antsaklis; Athanassios-Meletios Dimopoulos; Christos A Papadimitriou
Journal:  Mol Biol Rep       Date:  2012-10-12       Impact factor: 2.316

10.  Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer.

Authors:  James L Murray; Patricia Thompson; Suk Young Yoo; Kim-Anh Do; Mala Pande; Renke Zhou; Yanhong Liu; Aysegul A Sahin; Melissa L Bondy; Abenaa M Brewster
Journal:  Breast Cancer Res Treat       Date:  2013-03-26       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.